← board
TXMD
distress 6/10 · elevated risk$2.05+1%today-26% from 52w high
Revenue
pre-revenue
Liquidity
$8M
Runway
0.1 yrs
Shares 1y
0%
Price & events
-19.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.5%
1D
+0.5%
1W
+2.5%
1M
-6.0%
3M
-21.5%
6M
+70.8%
1Y
+14.5%
2Y
-96.1%
5Y
-96.7%
All
Overview
- Market Cap
- $23.73M
- Volume
- 6.21K
- 52 Week Range
- $1.04 – $2.77
- Total Shares
- 11.57M
- Float Shares
- 9.49M
- Short %
- 0.68%
- % Held by Insiders
- 7.45%
- % Held by Institutions
- 34.01%
- RVOL
- 0.15x
- Beta
- 0.59
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 11,574,362 · 0 offerings/1y · 0 PIPEs
- 2024-11-12SC 13Gstrategic_stake
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.